• JAN 11 2018

    Lunch for Hungry Minds with Dr. Benjamin Free – Jan. 18, 2018

    Dr. Benjamin Free, a collaborator with Oncoceutics on the effects of ONC201 and ONC206 on the dopamine receptor, will be presenting his research at the University City Science Center as part of the Science Center’s Lunch for Hungry Minds program. While blockade of the D2 dopamine receptor (D2R) is known to be required and primarily

    • OCT 26 2017

    ONC201 Biomarkers and Pharmacology at ENA Conference October 27-29th in Philadelphia

    Three abstracts involving Oncoceutics’ lead clinical compound, ONC201, will be presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia on October 28th and 29th, 2017. ONC201 is the first Dopamine Receptor 2 (DRD2) antagonist for clinic oncology and the first imipridone to enter the clinic, with 8 active clinical trials